Company / Shareholders' Equity
Processa Pharmaceuticals, Inc. Shareholders' Equity History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$25.5M
FY2022
5-year range
-$2.0M / $25.5M
FY2018-FY2022
Trend
+11.1%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$2M to $25M over the past 6 years.
Based on SEC 10-K filings.
$25M in FY2022.
Improved from -$2M to $25M over the past 6 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, shareholders' equity increased 11.1% year-over-year.
- Lowest shareholders' equity in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $25.5M | +11.1% |
| FY2021 | $22.9M | +1259.3% |
| FY2016 | -$2.0M | +0.0% |
| FY2015 | -$2.0M | -263.8% |
| FY2014 | $1.2M | -27.7% |
| FY2013 | $1.7M | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026